Hedge Funds: Why the highly coveted CEO meeting is overrated

 The Mentor vs The Apprentice

No one knows how to dig out jewels and reposition a business via accretive, bolt-on M&A like Colin Day who led strategic repositioning at Reckitt Benckiser (“RB”) as a hands-on CFO far more than most appreciate. Moreover, a high conviction investor could have accrued gains as large as 1000%[1] in RB during Colin’s tenure – under the aegis of Bart Becht. Today, Colin is the CEO of Essentra plc (fka Filtrona) and serves as a reminder of the dangers of subconsciously dismissing underlings, namely strategic CFOs.

[1] Aided by leveraging equity options

The Dream Team

In September 2000, Colin Day joined RB, a consumer products conglomerate[1], and together with Bart Becht racked up an enviable track record of capital allocation and a rousing share price appreciation[2].

[1] Includes the likes of Durex condoms, cleaning agensts Harpix & Dettol along with various OTC drugs

[2] During Colin’s intial month shares traded at low ~800p to £34.39

Click here for the full write-up

#portfolio #hedgefunds #publicmarkets

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s